BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: He SL, Shen J, Sun XJ, Zhu XJ, Liu LM, Dong JC. Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. World J Gastroenterol 2013; 19(28): 4552-4558 [PMID: 23901232 DOI: 10.3748/wjg.v19.i28.4552] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Goldstein R, Yu D, Gillmore R, Thirlwell C, O'Donoghue P, Mayer A, Meyer T. Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. Future Oncol 2014;10:2007-14. [PMID: 25209630 DOI: 10.2217/fon.14.108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Pelizzaro F, Sammarco A, Dadduzio V, Pastorelli D, Giovanis P, Soldà C, Rizzato MD, Lombardi G, Lonardi S, Peserico G, Imondi A, Sartori A, Maddalo G, Farinati F. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience. Digestive and Liver Disease 2019;51:1713-9. [DOI: 10.1016/j.dld.2019.06.015] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
3 Ravaioli M, Cucchetti A, Pinna AD, De Pace V, Neri F, Barbera MA, Maroni L, Frega G, Palloni A, De Lorenzo S, Ripoli MC, Pantaleo MA, Cescon M, Del Gaudio M, Brandi G. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. Sci Rep 2017;7:11305. [PMID: 28900245 DOI: 10.1038/s41598-017-11810-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
4 Lei C, Ren D, Fu M, Sun C, Ren H, Pan Q, Li Y. Curative effect of endostar combined with oxaliplatin in the treatment of primary hepatic carcinoma and its influence on immune cells. Oncol Lett 2019;17:3665-70. [PMID: 30881491 DOI: 10.3892/ol.2019.10022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Qin S, Gong X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. Hepat Oncol 2016;3:71-81. [PMID: 30191027 DOI: 10.2217/hep.15.42] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Liu L, Zheng YH, Han L, Qin SK. Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies. Medicine (Baltimore) 2016;95:e4993. [PMID: 27749557 DOI: 10.1097/MD.0000000000004993] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. Oxaliplatin-based chemotherapy: a new option in advanced hepatocellular carcinoma. a systematic review and pooled analysis. Clin Oncol (R Coll Radiol). 2014;26:488-496. [PMID: 24856442 DOI: 10.1016/j.clon.2014.04.031] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
8 Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol 2018;144:403-14. [PMID: 29249005 DOI: 10.1007/s00432-017-2556-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
9 Guo Y, Wang Q, Yang ZJ. Correlation between expression of CDC25A and Doppler ultrasound features in primary hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2013; 21(26): 2649-2654 [DOI: 10.11569/wcjd.v21.i26.2649] [Reference Citation Analysis]